Contract with the UK Government provides for the start of tests in September and will last for seven years.
One will be tested BioNTech vaccine against cancerstill this year.
The company signed a contract with the Government of UKto start tests in that country in September from 2023.
The idea is to extend this vaccination schedule until 2030being delivered 10 thousand doses over those seven years.
Early access to these tests will be given to early and advanced stage patients of cancer.
The novelty will encompass personalized therapies, including cancer vaccines, which try to stimulate the immune system to attack harmful cells.
The German company, responsible for one of the priority vaccines in the fight against COVID-19, will create new research and development centers in the United Kingdom.
The British Government explained in CNBC that this will be a private investment supported by a new launch platform for a cancer vaccine, from the local national health system.
“Our goal is to accelerate the development of immunotherapies and vaccines, using technologies we’ve been researching for over 20 years”, commented Ugur Sahin, president of BioNtech.
It is still too early to predict prices and distribution of the vaccine, said a government spokesman.
Moderna and Merck last month announced positive preliminary results for their developing messenger RNA vaccine against skin cancer when taken in combination with an anticancer drug.
ZAP // 
